Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cell Medica Opens Commercial Manufacturing Facility in Germany

Published: Thursday, September 26, 2013
Last Updated: Thursday, September 26, 2013
Bookmark and Share
Commercial launch of Cytovir CMV is planned for early 2014.

Imperial Innovations Group plc has announced that portfolio company Cell Medica has opened a European manufacturing facility in Berlin-Buch, Germany.

T cell immunotherapy involves harnessing the human immune system to treat diseases and Cell Medica is using the approach to develop, manufacture and market treatments of infections and cancers related to oncogenic (cancer-causing) viruses.

Cell Medica’s commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology area of Campus Berlin-Buch includes approximately 350 m2 clean room space, and will initially focus on manufacturing the company’s Cytovir™ CMV.

The innovative Cytovir CMV treatment uses immune cells of a healthy donor to restore immunity to Cytomegalovirus infections in patients who have lost their immunity following a bone marrow transplant.

The commercial launch of Cytovir CMV is planned for early 2014, following the completion of two randomized controlled studies currently ongoing in the UK.

The financing of Cell Medica’s investment in the Berlin-Buch facility is supported in part by the Investitionsbank Berlin (IBB), the business development and promotion bank of the Federal Land of Berlin.

The facility will also be important in providing investigational medicine products for Cell Medica’s planned CITADEL study to investigate a T cell therapy for the treatment of EBV-associated lymphomas, which will be undertaken following the required regulatory approvals.

Cell Medica is one of Innovations’ leading portfolio companies and represents the strength in depth of the Group’s top ten assets. In July 2012, Innovations committed £3 million as part of a £17 million funding round for Cell Medica. Innovations holds a 30% stake in the business.

Russ Cummings, Chief Executive Officer, Imperial Innovations, said: “The opening of a European manufacturing facility is a significant step towards Cell Medica bringing its lead product, Cytovir CMV, to market. We have been able to scale-up our investment over time to help Cell Medica’s excellent team maintain its industry-leading position and grow the value of the company.”

Dr Rainer Knaus, Managing Director of Cell Medica GmbH, said: “This facility has been designed and equipped to provide high quality Good Manufacturing Practice (GMP) compliant production of patient-specific cell and gene therapies for distribution across Europe. We are also very fortunate to have attracted highly educated and well-trained personnel who are keen to help shape this new era of cell-based therapeutics. These manufacturing specialists are preparing the facility for the supply of Cytovir CMV in early 2014.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Circassia’s Grass Allergy Treatment Achieves Significant Symptom Reduction
Circassia has achieved successful results from a large phase II clinical study of its grass allergy treatment.
Tuesday, October 08, 2013
Veryan Receives CE Mark Approval for BioMimics 3D™ Stent
A novel platform technology designed for treating the major arteries of the leg in patients with PAD.
Monday, November 19, 2012
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!